Abstract
Inhibition of intestinal P-glycoprotein might enhance the absorption of orally administered P-glycoprotein substrate drugs. We show here a 10-fold increased oral bioavailability of paclitaxel in mice treated with the P-glycoprotein blocker SDZ PSC 833. These results encourage further research on the development of a clinically useful oral formulation of paclitaxel.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
van Asperen, J., van Tellingen, O., Sparreboom, A. et al. Enhanced oral bioavailability of paclitaxel in mice treated with the P-glycoprotein blocker SDZ PSC 833. Br J Cancer 76, 1181–1183 (1997). https://doi.org/10.1038/bjc.1997.530
Issue Date:
DOI: https://doi.org/10.1038/bjc.1997.530
This article is cited by
-
Pharmacokinetic drug interactions between apigenin, rutin and paclitaxel mediated by P-glycoprotein in rats
European Journal of Drug Metabolism and Pharmacokinetics (2015)
-
Oral co-administration of elacridar and ritonavir enhances plasma levels of oral paclitaxel and docetaxel without affecting relative brain accumulation
British Journal of Cancer (2014)
-
Role of pregnane X receptor in chemotherapeutic treatment
Cancer Chemotherapy and Pharmacology (2014)
-
Oral Anticancer Drugs: Mechanisms of Low Bioavailability and Strategies for Improvement
Clinical Pharmacokinetics (2013)
-
Paclitaxel in self-micro emulsifying formulations: oral bioavailability study in mice
Investigational New Drugs (2011)
